Hims & Hers Health shares fall nearly 14% as selling intensifies despite analyst upgrades and strategic expansion

Traders Union
All News
Stocks
Hims & hers health slides 13.68% today

Highlights

Analysts upgraded Hims & Hers Health to 'Buy' following operational discipline and regulatory momentum supporting expanded personalized treatments and telehealth offerings.
Management targets $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, backed by $974 million in convertible notes.
Shares face broad seller pressure, trading below major averages; next five-day range expected between $24.45 and $30.78, with mixed technical signals and a consolidation bias.

Analyst upgrades amid revenue targets fail to reverse broad selling

Hims & Hers Health Inc. was upgraded by several analysts from 'Hold' to 'Buy', citing the company’s operational discipline and strategic steps in expanding personalized treatments and telehealth. The firm leveraged recent FDA panel momentum for peptides to enhance its portfolio and maintained a focus on clinical rigor and supply chain transparency. The company holds $974 million in convertible notes and has set long-term targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, alongside its ongoing financial growth efforts. These developments were accompanied by a continued focus on execution, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, observes that Hims & Hers Health faces sustained weakness as it trades below critical moving averages. He notes that heavy selling persists despite analyst upgrades and strategic expansion efforts. Technical momentum remains mixed, with failed upside attempts and increased volatility suggesting fragile sentiment. The company’s ambitious long-term targets seem disconnected from current price action and convertible note liabilities raise further doubts. "The setup points to unresolved risk and additional downside cannot be dismissed in the near term."

Viktoras Karapetjanc, expert at Traders Union, highlights management’s operational discipline and recent analyst upgrades as drivers of renewed confidence. He underscores the company’s strong long-term revenue and EBITDA targets, backed by portfolio expansion and FDA-related innovation. Improving sentiment and buy signals from MACD suggest opportunities for momentum buyers. "Bullish structure remains intact and further growth is expected as execution aligns with the market’s evolving demands."

Jainam Mehta, market strategist, sees price consolidating in a defined $24.45–$30.78 range after a sharp drop and mixed technicals. He points to RSI and Stochastic RSI indicating oversold conditions, hinting at potential tactical rebound setups. Momentum signals remain divided, making risk management essential. "A potential breakout above $28.31 could offer a contrarian entry for nimble traders."

Bearish trend sustained as mixed momentum and support limits guide action

Hims & Hers Health is trading below its 20-day, 50-day, and 200-day moving averages ($34.63, $30.24, and $31.19). This positioning points to seller dominance and underscores a bearish trend across short-, medium-, and long-term horizons. The near-term resistance sits at $28.31, while the floor is set at $24.45, with the MA-50 vs MA-200 structure reinforcing a negative long-term bias. Momentum signals are mixed: MACD shows strong buy momentum, but ADX signals neutrality. RSI stands at 48.98 with a sell signal, also supported by a bearish CCI. Stochastic RSI at 15.02 highlights an oversold condition. Bull/Bear Power (BBP) at 2.13 shows buyers dominated intraday, but the metric flags an overbought state. The Awesome Oscillator remains neutral. The stock opened with an upside gap of approximately $0.72 (2.2%) but last traded near today’s low, reflecting increasing intraday volatility at 21.23% and a shift from early demand to sustained selling into the close, amid mixed momentum and oscillator signals.

Earlier, analysts noted that Hims & Hers Health remained under persistent selling pressure with a broadly bearish technical outlook. While the current session reinforces this negative momentum, traders should remain alert to a potential shift in direction if volatility persists near the projected range boundaries in the days ahead.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.